Voyager Therapeutics (VYGR) · VY7523
Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: second half of 2026
Enrollment in this MAD clinical trial was completed in the fourth quarter of 2025, and we expect initial tau positron emission tomography imaging efficacy data in the second half of 2026.
· filed · SEC filing
After
Stated timing: Q4 2026
Voyager expects tau positron emission tomography (PET) imaging efficacy data in Q4 2026 from the ongoing multiple ascending dose (MAD) clinical trial in participants with Alzheimer’s disease (AD).
SEC original · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/VYGR-vy7523-2026-08-06, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/VYGR-vy7523-2026-08-06
Voyager Therapeutics (VYGR) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-Q is a company’s quarterly report to the SEC, with unaudited financial statements.